Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Joly, V.; Moroni, M.; Concia, Ercole; Lazzarin, A.; Hirschel, Bernard; Jost, J.; Chiodo, F.; Bentwich, Z.; Love, W. C.; Hawkins, D. A.; Wilkins, E. G.; Gatell, A. J.; Vetter, N.; Greenwald, C.; Freimuth, W. W.; de Cian, W.

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group
Authors		Joly, V. Moroni, M. Concia, Ercole Lazzarin, A. Hirschel, Bernard Jost, J. Chiodo, F. Bentwich, Z. Love, W. C. Hawkins, D. A. Wilkins, E. G. Gatell, A. J. Vetter, N. Greenwald, C. Freimuth, W. W. de Cian, W. show all authors [1 - 16]
Published in		Antimicrobial Agents and Chemotherapy. 2000, vol. 44, no. 11, p. 3155-3157
Abstract		We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
Keywords		Anti-HIV Agents/ therapeutic use — Delavirdine/ therapeutic use — Double-Blind Method — Drug Resistance, Microbial — Drug Therapy, Combination — HIV Infections/ drug therapy — HIV Reverse Transcriptase/genetics — HIV-1/drug effects/genetics — Humans — Treatment Outcome — Zidovudine/therapeutic use
Identifiers		PMID: 11036040
Full text		Article - Limited access to UNIGE Other version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC101620/pdf/ac003155.pdf
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités
Citation (ISO format)		JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial Agents and Chemotherapy, 2000, vol. 44, n° 11, p. 3155-3157. https://archive-ouverte.unige.ch/unige:7355